Skip to main content
NCD 280.14 · version 2

NCD 280.14: Infusion Pumps

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 280.14

Benefit category
Durable Medical Equipment
Effective date
12/17/2004
Implemented 02/18/2005
Transmittal
Transmittal 27
Versions published
2
Manual section
280
Medical and Surgical Supplies, NCD Manual (Pub. 100-03) chapter 1 part 4

TL;DR

NCD 280.14 sets Medicare's national policy for infusion pumps under the benefit category "Durable Medical Equipment", effective 12/17/2004 and implemented 02/18/2005. The following indications for treatment using infusion pumps are covered under Medicare: It has been revised 1 time since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. General

Infusion pumps are medical devices used to deliver solutions containing parenteral drugs under pressure at a regulated flow rate.

Indications and limitations of coverage

B. Nationally Covered Indications

The following indications for treatment using infusion pumps are covered under Medicare:

1. External Infusion Pumps

a. Iron Poisoning (Effective for Services Performed On or After September 26, 1984)

When used in the administration of deferoxamine for the treatment of acute iron poisoning and iron overload, only external infusion pumps are covered.

b. Thromboembolic Disease (Effective for Services Performed On or After September 26, 1984)

When used in the administration of heparin for the treatment of thromboembolic disease and/or pulmonary embolism, only external infusion pumps used in an institutional setting are covered.

c. Chemotherapy for Liver Cancer (Effective for Services Performed On or After January 29, 1985)

The external chemotherapy infusion pump is covered when used in the treatment of primary hepatocellular carcinoma or colorectal cancer where this disease is unresectable; OR, where the patient refuses surgical excision of the tumor.

d. Morphine for Intractable Cancer Pain (Effective for Services Performed On or After April 22, 1985)

Morphine infusion via an external infusion pump is covered when used in the treatment of intractable pain caused by cancer (in either an inpatient or outpatient setting, including a hospice).

e. Continuous Subcutaneous Insulin Infusion (CSII) Pumps (Effective for Services Performed On or after December 17, 2004)

Continuous subcutaneous insulin infusion (CSII) and related drugs/supplies are covered as medically reasonable and necessary in the home setting for the treatment of diabetic patients who: (1) either meet the updated fasting C-Peptide testing requirement, or, are beta cell autoantibody positive; and, (2) satisfy the remaining criteria for insulin pump therapy as described below. Patients must meet either Criterion A or B as follows:

Criterion A: The patient has completed a comprehensive diabetes education program, and has been on a program of multiple daily injections of insulin (i.e., at least 3 injections per day), with frequent self-adjustments of insulin doses for at least 6 months prior to initiation of the insulin pump, and has documented frequency of glucose self-testing an average of at least 4 times per day during the 2 months prior to initiation of the insulin pump, and meets one or more of the following criteria while on the multiple daily injection regimen:

• Glycosylated hemoglobin level (HbAlc) > 7.0%;

• History of recurring hypoglycemia;

• Wide fluctuations in blood glucose before mealtime;

• Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dl; or,

• History of severe glycemic excursions.

Criterion B: The patient with diabetes has been on a pump prior to enrollment in Medicare and has documented frequency of glucose self-testing an average of at least 4 times per day during the month prior to Medicare enrollment.

General CSII Criteria

In addition to meeting Criterion A or B above, the following general requirements must be met:

The patient with diabetes must be insulinopenic per the updated fasting C-peptide testing requirement, or, as an alternative, must be beta cell autoantibody positive.

Updated fasting C-peptide testing requirement:

• Insulinopenia is defined as a fasting C-peptide level that is less than or equal to 110% of the lower limit of normal of the laboratory's measurement method.

• For patients with renal insufficiency and creatinine clearance (actual or calculated from age, gender, weight, and serum creatinine) ≤ 50 ml/minute, insulinopenia is defined as a fasting C-peptide level that is less than or equal to 200% of the lower limit of normal of the laboratory's measurement method.

• Fasting C-peptide levels will only be considered valid with a concurrently obtained fasting glucose ≤ 225 mg/dL.

• Levels only need to be documented once in the medical records.

Continued coverage of the insulin pump would require that the patient be seen and evaluated by the treating physician at least every 3 months.

The pump must be ordered by and follow-up care of the patient must be managed by a physician who manages multiple patients with CSII and who works closely with a team including nurses, diabetes educators, and dietitians who are knowledgeable in the use of CSII.

Other Uses of CSII

The Centers for Medicare & Medicaid Services will continue to allow coverage of all other uses of CSII in accordance with the Category B investigational device exemption clinical trials regulation (42 CFR 405.201) or as a routine cost under the clinical trials policy (Medicare National Coverage Determinations Manual 310.1 ).

f. Other Uses

Other uses of external infusion pumps are covered if the Medicare Administrative Contractor (MAC) medical staff verifies the appropriateness of the therapy and the prescribed pump for the individual patient.

NOTE: Payment may also be made for drugs necessary for the effective use of a covered external infusion pump as long as the drug being used with the pump is itself reasonable and necessary for the patient's treatment.

2. Implantable Infusion Pumps

a. Chemotherapy for Liver Cancer (Effective for Services Performed On or After September 26, 1984)

The implantable infusion pump is covered for intra-arterial infusion of 5-FUdR for the treatment of liver cancer for patients with primary hepatocellular carcinoma or Duke's Class D colorectal cancer, in whom the metastases are limited to the liver, and where: (1) the disease is unresectable, or, (2) the patient refuses surgical excision of the tumor.

b. Anti-Spasmodic Drugs for Severe Spasticity

An implantable infusion pump is covered when used to administer anti-spasmodic drugs intrathecally (e.g., baclofen) to treat chronic intractable spasticity in patients who have proven unresponsive to less invasive medical therapy as determined by the following criteria:

As indicated by at least a 6-week trial, the patient cannot be maintained on non-invasive methods of spasm control, such as oral anti-spasmodic drugs, either because these methods fail to control adequately the spasticity or produce intolerable side effects. And prior to pump implantation, the patient must have responded favorably to a trial intrathecal dose of the anti-spasmodic drug.

c. Opioid Drugs for Treatment of Chronic Intractable Pain

An implantable infusion pump is covered when used to administer opioid drugs (e.g., morphine) intrathecally or epidurally for treatment of severe chronic intractable pain of malignant or nonmalignant origin in patients who have a life expectancy of at least 3 months, and who have proven unresponsive to less invasive medical therapy as determined by the following criteria:

The patient's history must indicate that he/she would not respond adequately to noninvasive methods of pain control, such as systemic opioids (including attempts to eliminate physical and behavioral abnormalities which may cause an exaggerated reaction to pain); and a preliminary trial of intraspinal opioid drug administration must be undertaken with a temporary intrathecal/epidural catheter to substantiate adequately acceptable pain relief and degree of side effects (including effects on the activities of daily living) and patient acceptance.

d. Coverage of Other Uses of Implanted Infusion Pumps

Determinations may be made on coverage of other uses of implanted infusion pumps if the MAC medical staff verifies that:

• The drug is reasonable and necessary for the treatment of the individual patient;

• It is medically necessary that the drug be administered by an implanted infusion pump; and,

• The Food and Drug Administration-approved labeling for the pump must specify that the drug being administered and the purpose for which it is administered is an indicated use for the pump.

e. Implantation of Infusion Pump Is Contraindicated

The implantation of an infusion pump is contraindicated in the following patients:

With a known allergy or hypersensitivity to the drug being used (e.g., oral baclofen, morphine, etc.);or,

Who have an active infection;or,

Whose body size is insufficient to support the weight and bulk of the device; or,

With other implanted programmable devices since crosstalk between devices may inadvertently change the prescription.

NOTE: Payment may also be made for drugs necessary for the effective use of an implantable infusion pump as long as the drug being used with the pump is itself reasonable and necessary for the patient's treatment.

C. Nationally Non-Covered Indications

The following indications for treatment using infusion pumps are not covered under Medicare:

1. External Infusion Pumps

Vancomycin (Effective for Services Beginning On or After September 1, 1996)

Text reproduced from the CMS Medicare Coverage Database record for NCD 280.14 version 2. View the original on cms.gov.

Local policies that build on this NCD

4 active Local Coverage Determinations cite NCD 280.14 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

How MACs bill NCD 280.14

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 5 current articles in the Medicare Coverage Database name NCD 280.14, 5 of them with a covered ICD-10-CM list, from 5 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A52507: External Infusion Pumps - Policy Article

Article, effective 2026-10-01 · CGS Administrators, LLC (17013, 18003); Noridian Healthcare Solutions, LLC (16013, 19003) · CMS record

460 covered ICD-10-CM codes in 6 groups. Local policy: L33794 External Infusion Pumps.

First covered codes: E08.00 Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC); E08.01 Diabetes mellitus due to underlying condition with hyperosmolarity with coma; E08.10 Diabetes mellitus due to underlying condition with ketoacidosis without coma; E08.11 Diabetes mellitus due to underlying condition with ketoacidosis with coma; E08.21 Diabetes mellitus due to underlying condition with diabetic nephropathy; E08.22 Diabetes mellitus due to underlying condition with diabetic chronic kidney disease; …

A56651: Billing and Coding: Epidural Steroid Injections for Pain Management

Billing and Coding, effective 2023-11-16 · First Coast Service Options, Inc. (09101, 09102, 09201, 09202, 09302) · CMS record

47 covered ICD-10-CM codes; 6 procedure codes: 62321, 62323, 64479, 64480, 64483, 64484. Local policy: L33906 Epidural Steroid Injections for Pain Management, L39799 Cervical Fusion. Check a diagnosis for 62321.

First covered codes: B02.23 Postherpetic polyneuropathy; B02.7 Disseminated zoster; B02.8 Zoster with other complications; B02.9 Zoster without complications; G89.3 Neoplasm related pain (acute) (chronic); M47.22 Other spondylosis with radiculopathy, cervical region; …

A56681: Billing and Coding: Epidural Steroid Injections for Pain Management

Billing and Coding, effective 2023-11-16 · Novitas Solutions, Inc. (04111, 04112, 04211, 04212, 04311, 04312, 04411, 04412, 04911, 07101, 07102, 07201, 07202, 07301, 07302, 12101, 12102, 12201, 12202, 12301, 12302, 12401, 12402, 12501, 12502, 12901) · CMS record

47 covered ICD-10-CM codes; 6 procedure codes: 62321, 62323, 64479, 64480, 64483, 64484. Local policy: L36920 Epidural Steroid Injections for Pain Management, L39793 Cervical Fusion. Check a diagnosis for 62321.

First covered codes: B02.23 Postherpetic polyneuropathy; B02.7 Disseminated zoster; B02.8 Zoster with other complications; B02.9 Zoster without complications; G89.3 Neoplasm related pain (acute) (chronic); M47.22 Other spondylosis with radiculopathy, cervical region; …

A58695: Billing and Coding: Epidural Steroid Injections for Pain Management

Billing and Coding, effective 2023-11-16 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

46 covered ICD-10-CM codes; 8 procedure codes: 62320, 62321, 62322, 62323, 64479, 64480, 64483, 64484. Local policy: L38994 Epidural Steroid Injections for Pain Management. Check a diagnosis for 62320.

First covered codes: B02.23 Postherpetic polyneuropathy; B02.7 Disseminated zoster; B02.8 Zoster with other complications; B02.9 Zoster without complications; G89.3 Neoplasm related pain (acute) (chronic); M47.22 Other spondylosis with radiculopathy, cervical region; …

A58731: Billing and Coding: Epidural Steroid Injections for Pain Management

Billing and Coding, effective 2025-03-13 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

46 covered ICD-10-CM codes; 8 procedure codes: 62320, 62321, 62322, 62323, 64479, 64480, 64483, 64484. Local policy: L39015 Epidural Steroid Injections for Pain Management. Check a diagnosis for 62320.

First covered codes: B02.23 Postherpetic polyneuropathy; B02.7 Disseminated zoster; B02.8 Zoster with other complications; B02.9 Zoster without complications; G89.3 Neoplasm related pain (acute) (chronic); M47.22 Other spondylosis with radiculopathy, cervical region; …

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 3 analyses to NCD 280.14, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00041N Insulin Infusion Pump (New, Closed)
  2. CAG-00092N Insulin Pump: C-Peptide Levels as a Criterion for Use (New, Closed)
  3. CAG-00092R Insulin Pump: C-Peptide Levels as a Criterion for Use (1st Recon, Closed)

Revision history

02/2005 - Added positive fasting beta cell autoantibody test as adequate diagnostic criterion for alternative to insulinopenia per the updated C-peptide testing requirement. Effective date 12/17/2004. Implementation date 2/18/2005. ( TN 27 ) (CR 3705)

09/2001 - Revised C-peptide requirement to less than or equal to 110 percent of lower limit of normal of laboratory's measurement method. This change expanded value of laboratory test to be considered in determining coverage of insulin infusion pump for all diabetic patients. (Type II diabetics no longer excluded.) Effective and implementation dates 01/01/2002. ( TN 143 ) (CR 1814)

12/1999 - Revised noncovered policy to limited coverage for continuous subcutaneous insulin infusion pumps. Effective and implementation dates 04/01/2000. (TN 120) (CR 1010)

03/1997 - Specified that implantable infusion pumps for delivery of insulin to treat diabetes is not covered. Effective date 04/15/1997. (TN 93)

06/1996 - Excluded coverage of vancomycin used with an external infusion pump. Effective date 09/01/1996. (TN 86)

02/1994 - Provided coverage of implantable infusion pumps for use in treatment of spasticity and chronic intractable pain of malignant or nonmalignant origin, if specified patient selection criteria met. Effective date 03/04/1994. (TN 67)

03/1992 - Added pages that were inadvertently omitted when manual was reprinted. Effective date NA. (TN 57)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 280.14

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 280.14

What does NCD 280.14 cover?

The following indications for treatment using infusion pumps are covered under Medicare: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 280.14 take effect?

The current version (2) is effective 12/17/2004, implemented 02/18/2005, published in transmittal 27. CMS lists 2 versions of this NCD.

Does a Local Coverage Determination override NCD 280.14?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.